Targeted oncology focus Bluprint Oncology specializes in oncology and hematology as a medical strategy and communications partner, presenting a clear opportunity to upsell specialized advertising services, strategic messaging, and stakeholder engagement programs to pharma and biotech firms focusing on cancer therapies.

Petauri ecosystem leverage As part of Petauri Advance, Bluprint can align with a broader pharmaceutical service platform, enabling cross-sell into global market access, HEOR, patient services, data analytics, and medical affairs to offer integrated solutions.

Digital and social storytelling Their emphasis on bringing stories from podiums at ASCO to social media suggests demand for advanced digital campaigns, content localization, multi-channel strategy, and performance analytics to optimize reach and engagement for oncology products.

Moderate scale with growth potential With 51-200 employees and reported revenue in the mid to high six figures, Bluprint offers a nimble, scalable team for pilot programs or selective engagements, while leaving room for expansion through larger pharma partnerships.

Tech stack and modernization Existing use of LinkedIn Ads, AWS, Google Cloud, and a web-enabled stack indicates readiness for data-driven marketing, programmatic campaigns, and analytics-led insights, presenting opportunities to sell robust martech solutions and optimization services.